Role of radiation in oligo-progression in EGFR mutated metastatic non small cell lung cancer

被引：0
|
作者：
Rathee, N. [1 ]
Arunsingh, M. [1 ]
Bhattacharyya, T. [1 ]
Majumder, P. [1 ]
Chowdhury, O. [1 ]
Shah, S. [1 ]
机构：
[1] Tata Med Ctr, Kolkata, India
来源：
CLINICAL ONCOLOGY | 2024年 / 36卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
HAB035
引用
收藏
页码：E367 / E367
页数：1
相关论文
共 50 条
  • [21] Gefitinib or Chemotherapy for Non-Small-Cell Lung Cancer with Mutated EGFR.
    Maemondo, Makoto
    Inoue, Akira
    Kobayashi, Kunihiko
    Sugawara, Shunichi
    Oizumi, Satoshi
    Isobe, Hiroshi
    Gemma, Akihiko
    Harada, Masao
    Yoshizawa, Hirohisa
    Kinoshita, Ichiro
    Fujita, Yuka
    Okinaga, Shoji
    Hirano, Haruto
    Yoshimori, Kozo
    Harada, Toshiyuki
    Ogura, Takashi
    Ando, Masahiro
    Miyazawa, Hitoshi
    Tanaka, Tomoaki
    Saijo, Yasuo
    Hagiwara, Koichi
    Morita, Satoshi
    Nukiwa, Toshihiro
    NEW ENGLAND JOURNAL OF MEDICINE, 2010, 362 (25): : 2380 - 2388
  • [22] Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer
    Wu, Yi-Long
    Tsuboi, Masahiro
    He, Jie
    John, Thomas
    Grohe, Christian
    Majem, Margarita
    Goldman, Jonathan W.
    Laktionov, Konstantin
    Kim, Sang-We
    Kato, Terufumi
    Vu, Huu-Vinh
    Lu, Shun
    Lee, Kye-Young
    Akewanlop, Charuwan
    Yu, Chong-Jen
    de Marinis, Filippo
    Bonanno, Laura
    Domine, Manuel
    Shepherd, Frances A.
    Zeng, Lingmin
    Hodge, Rachel
    Atasoy, Ajlan
    Rukazenkov, Yuri
    Herbst, Roy S.
    NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (18): : 1711 - 1723
  • [23] Clinical Benefit of EGFR-TKIs Plus Radiotherapy for Treating EGFR-Mutated Metastatic Non-Small-Cell Lung Cancer
    Li, T.
    Wang, R.
    Lv, J.
    Sun, C.
    Shi, Q.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2019, 105 (01): : E516 - E517
  • [24] Dacomitinib for the first-line treatment of patients with EGFR-mutated metastatic non-small cell lung cancer
    Santarpia, Mariacarmela
    Menis, Jessica
    Chaib, Imane
    Cao, Maria Gonzalez
    Rosell, Rafael
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2019, 12 (09) : 831 - 840
  • [25] Pattern of Disease Progression on Osimertinib and Subsequent Treatment in Patients with EGFR-Mutated Non-Small Cell Lung Cancer
    Kim, H.
    Han, J.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1120 - S1120
  • [26] Clinical Experience With 75-mg Dose of Erlotinib for Mutated Metastatic EGFR Non-small Cell Lung Cancer
    Aren, Osvaldo
    Samtani, Suraj
    Frelinghuysen, Micahel
    Burotto, Mauricio
    AMERICAN JOURNAL OF THERAPEUTICS, 2021, 28 (04) : E375 - E379
  • [27] Osimertinib beyond Progression in Patients with EGFR Mutated Non-small Cell Lung Cancer (NSCLC) Receiving Frontline Osimertinib
    Benyounes, A.
    Cohen, A.
    Rossi, S. Diamond
    Cannon, T.
    Yacur, M.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S657 - S657
  • [28] Fatty acid synthase mediates EGFR palmitoylation in EGFR mutated non-small cell lung cancer
    Ali, Azhar
    Levantini, Elena
    Teo, Jun Ting
    Goggi, Julian
    Clohessy, John G.
    Wu, Chan Shuo
    Chen, Leilei
    Yang, Henry
    Krishnan, Indira
    Kocher, Olivier
    Zhang, Junyan
    Soo, Ross A.
    Bhakoo, Kishore
    Chin, Tan Min
    Tenen, Daniel G.
    EMBO MOLECULAR MEDICINE, 2018, 10 (03)
  • [29] Clinical benefit of EGFR-TKIs plus radiotherapy for treating EGFR-mutated metastatic non-small cell lung cancer.
    Wang, Ran Lin
    Li, Tao
    Lv, Jiahua
    Sun, Chang
    Shi, Qiuling
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [30] Leptomeningeal carcinomatosis from EGFR-mutated non-small cell lung cancer
    Iuchi, T.
    Shingyoji, M.
    Setoguchi, T.
    Yoshida, Y.
    Ashinuma, H.
    Hasegawa, Y.
    Sakaida, T.
    ANNALS OF ONCOLOGY, 2017, 28
12345